These results showed that betaine-mediated PPARα activation, GA-mediated inactivation of CASP3, UA-mediated downregulation of CASP8, and wogonin-mediated inactivation of NFκB may be the potential mechanisms of Ganweikang tablet in the treatment of NAFLD. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.